Hippo Pathway in Cancer: Aberrant Regulation and Therapeutic Opportunities

被引:302
作者
Calses, Philamer C. [1 ,2 ]
Crawford, James J. [3 ]
Lill, Jennie R. [2 ]
Dey, Anwesha [1 ]
机构
[1] Genentech Inc, Dept Discovery Oncol, 1 DNA Way, San Francisco, CA 94080 USA
[2] Genentech Inc, Dept Microchem Prote & Lipid, 1 DNA Way, San Francisco, CA 94080 USA
[3] Genentech Inc, Dept Discovery Chem, 1 DNA Way, San Francisco, CA 94080 USA
来源
TRENDS IN CANCER | 2019年 / 5卷 / 05期
关键词
SQUAMOUS-CELL CARCINOMA; EFFECTOR YAP; ANTITUBULIN DRUGS; RESISTANCE; TEAD; ACTIVATION; YAP/TAZ; OVEREXPRESSION; SENSITIVITY; INHIBITION;
D O I
10.1016/j.trecan.2019.04.001
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The Hippo pathway remains a central focus in both basic and translational research and is a key modulator of developmental biology. Dysregulation of the pathway is associated with a plethora of human cancers and there are multiple efforts to target key components of the pathway for disease intervention. In this review, we briefly highlight the latest research advances around the core components of the Hippo pathway in cancer. More specifically, we discuss several genetic aberrations of these factors as mechanisms for the development of cancers, including genetic amplification, deletion, and gene fusions. Additionally, we highlight the role of the Hippo pathway in cancer therapy resistance and tumor immunogenicity. Last, we summarize the ongoing efforts to target the pathway in cancers.
引用
收藏
页码:297 / 307
页数:11
相关论文
共 70 条
[61]   Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors [J].
Westover, D. ;
Zugazagoitia, J. ;
Cho, B. C. ;
Lovly, C. M. ;
Paz-Ares, L. .
ANNALS OF ONCOLOGY, 2018, 29 :I10-I19
[62]   A Functional Landscape of Resistance to ALK Inhibition in Lung Cancer [J].
Wilson, Frederick H. ;
Johannessen, Cory M. ;
Piccioni, Federica ;
Tamayo, Pablo ;
Kim, Jong Wook ;
Van Allen, Eliezer M. ;
Corsello, Steven M. ;
Capelletti, Marzia ;
Calles, Antonio ;
Butaney, Mohit ;
Sharifnia, Tanaz ;
Gabriel, Stacey B. ;
Mesirov, Jill P. ;
Hahn, William C. ;
Engelman, Jeffrey A. ;
Meyerson, Matthew ;
Root, David E. ;
Jaenne, Pasi A. ;
Garraway, Levi A. .
CANCER CELL, 2015, 27 (03) :397-408
[63]  
Wu X., 2017, Patent No. [2017/053706A1, 2017053706]
[64]   Mutant Gq/11 Promote Uveal Melanoma Tumorigenesis by Activating YAP [J].
Yu, Fa-Xing ;
Luo, Jing ;
Mo, Jung-Soon ;
Liu, Guangbo ;
Kim, Young Chul ;
Meng, Zhipeng ;
Zhao, Ling ;
Peyman, Gholam ;
Ouyang, Hong ;
Jiang, Wei ;
Zhao, Jiagang ;
Chen, Xu ;
Zhang, Liangfang ;
Wang, Cun-Yu ;
Bastian, Boris C. ;
Zhang, Kang ;
Guan, Kun-Liang .
CANCER CELL, 2014, 25 (06) :822-830
[65]   YAP/TAZ as therapeutic targets in cancer [J].
Zanconato, Francesca ;
Battilana, Giusy ;
Cordenonsi, Michelangelo ;
Piccolo, Stefano .
CURRENT OPINION IN PHARMACOLOGY, 2016, 29 :26-33
[66]   YAP/TAZ at the Roots of Cancer [J].
Zanconato, Francesca ;
Cordenonsi, Michelangelo ;
Piccolo, Stefano .
CANCER CELL, 2016, 29 (06) :783-803
[67]   Structure-Based Design and Synthesis of Potent Cyclic Peptides Inhibiting the YAP-TEAD Protein-Protein Interaction [J].
Zhang, Zhisen ;
Lin, Zhaohu ;
Zhou, Zheng ;
Shen, Hong C. ;
Yan, S. Frank ;
Mayweg, Alexander V. ;
Xu, Zhiheng ;
Qin, Ning ;
Wong, Jason C. ;
Zhang, Zhenshan ;
Rong, Yiping ;
Fry, David C. ;
Hu, Taishan .
ACS MEDICINAL CHEMISTRY LETTERS, 2014, 5 (09) :993-998
[68]   A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCFβ-TRCP [J].
Zhao, Bin ;
Li, Li ;
Tumaneng, Karen ;
Wang, Cun-Yu ;
Guan, Kun-Liang .
GENES & DEVELOPMENT, 2010, 24 (01) :72-85
[69]   Regulation of sensitivity of tumor cells to antitubulin drugs by Cdk1-TAZ signalling [J].
Zhao, Yulei ;
Yang, Xiaolong .
ONCOTARGET, 2015, 6 (26) :21906-21917
[70]   YAP-Induced Resistance of Cancer Cells to Antitubulin Drugs Is Modulated by a Hippo-Independent Pathway [J].
Zhao, Yulei ;
Khanal, Prem ;
Savage, Paul ;
She, Yi-Min ;
Cyr, Terry D. ;
Yang, Xiaolong .
CANCER RESEARCH, 2014, 74 (16) :4493-4503